Detalhe da pesquisa
1.
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
Eur Heart J
; 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38856678
2.
Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials.
Cardiovasc Drugs Ther
; 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38446275
3.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770629
4.
Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders.
Clin Infect Dis
; 75(1): e509-e515, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34971385
5.
Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.
JAMA Cardiol
; 8(11): 1070-1076, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37703006
6.
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.
Nat Med
; 29(3): 729-737, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879129
7.
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
Eur J Prev Cardiol
; 29(14): 1842-1851, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708715
8.
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes.
J Clin Lipidol
; 16(5): 747-756, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153281
9.
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Schizophr Bull
; 45(2): 350-359, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718385